Ultragenyx Pharmaceutical Inc. (RARE) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-04
(Q2 2026)
— full calendar
Earnings Reports
-
Ultragenyx (RARE) Q1 2026: 64% Ex-U.S. FKESA Growth Signals Pipeline-Driven Revenue Inflection
June 17, 2026
-
Ultragenyx (RARE) Q2 2025: Pipeline Drives 20% Revenue Growth as Phase III Programs Reach Inflection
June 16, 2026
-
Ultragenyx (RARE) Q3 2025: $400M Royalty Monetization Extends Runway Ahead of Transformative Readouts
June 16, 2026
-
Ultragenyx (RARE) Q1 2025: Latin America Drives 52% CRISVITA Growth, Unlocking Global Rare Disease Upside
July 07, 2025